Author

Ben Leatherdale

Institution: Adc Therapeutics (Switzerland)

Observed institution: Adc Therapeutics (Switzerland)

ORCID: 0009-0009-5532-0689

Observed ORCID: 0009-0009-5532-0689

OpenAlex ID: A5018728593

From 3-Tier to adaptive immunogenicity testing strategies: recommendations from the European Bioanalysis Forum

2026 · Kyra J. Cowan, Rob Nelson, et al. · Bioanalysis · 5

Recent discussions and proposals on challenging the 3-tier immunogenicity testing strategies from the European bioanalysis forum

2025 · Kyra J Cowan, Karien Bloem, et al. · Bioanalysis · 5

Abstract 2638: Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers

2023 · Francesca Zammarchi, Karin Havenith, et al. · Cancer Research · 3

Abstract 1580: HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers

2025 · Danilo Cucchi, Elizabeth Horsley, et al. · Cancer Research · 2

Abstract 6736: Preclinical development of ADCT-241, a novel exatecan-based antibody-drug conjugate targeting PSMA for the treatment of prostate cancer

2025 · Ben Leatherdale, Beccie Martin, et al. · Cancer Research · 2

Abstract 1604: Preclinical development of ADCT-211, a novel pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting solid tumors expressing IL13RA2

2023 · Francesca Zammarchi, Karin Havenith, et al. · Cancer Research · 2

Preclinical Characterization of ADCT-241, an Exatecan-Based Antibody–Drug Conjugate against PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer

2026 · Asma Jabeen, Ben Leatherdale, et al. · Molecular Cancer Therapeutics

Works count: 7

Citation count: 19

H-index: 3

I10-index: